Search for Articles:
Title / Keyword
Author / Affiliation / Email
Journal
Article Type
 
 
Advanced Search
 
Section
Special Issue
Volume
Issue
Number
Page
 
7.4
5.2
Journals
Cancers
Special Issues
Advances in the Diagnosis and Management of Uterine Sarcomas
share announcement

Advances in the Diagnosis and Management of Uterine Sarcomas

A special issue of Cancers (ISSN 2072-6694). This special issue belongs to the section "Cancer Causes, Screening and Diagnosis".

Deadline for manuscript submissions: closed (30 November 2023) | Viewed by 2227

Special Issue Editors

Dr. Ignacio Zapardiel

E-Mail Website
Guest Editor
Faculty of Medicine, University Hospital La Paz, Autonomous University of Madrid, 28049 Madrid, Spain
Interests: human papillomavirus; HPV vaccines; cervical cancer; cervical conization
Special Issues, Collections and Topics in MDPI journals
Dr. Myriam Gracia

E-Mail Website
Guest Editor
Gynecologic Oncology Unit, La Paz University Hospital, Madrid, Spain
Interests: uterine sarcoma, laparoscopy, gynecologic oncology
Special Issues, Collections and Topics in MDPI journals

Special Issue Information

Dear Colleagues,

Uterine sarcoma is a rare but aggressive disease that is frequently misdiagnosed preoperatively and presents controversy with respect to its management mainly due to a lack of strong evidence and lack of experience among practitioners in treatment centers.

Most patients suffering from uterine sarcomas arrive at the operating room with a diagnosis of fibroids; hence, intraoperative management may not be the most appropriate factor impacting the prognosis of the disease.

The main treatment in the disease’s initial stages seems to be complete surgical resection, while the roles of chemotherapy and radiotherapy remain very controversial. However, the treatment for advanced cases after surgery (when possible) is chemotherapy, although an optimal regimen has not been completely established.

This Special Issue aims to collect scientific evidence on the preoperative diagnosis of this disease, thereby helping surgeons approach surgical resection appropriately. In addition, it will attempt to clarify the role of chemotherapy and radiation therapy in the disease’s early and advanced stages according to the current knowledge.

Dr. Ignacio Zapardiel
Dr. Myriam Gracia
Guest Editors

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Cancers is an international peer-reviewed open access semimonthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2900 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.

Keywords

  • uterine sarcoma
  • surgical management
  • leiomyosarcoma
  • adenosarcoma
  • endometrial stromal sarcoma

Published Papers (2 papers)

Download All Papers
Order results
Result details
Show export options expand_more Show export options expand_less
Select all
Export citation of selected articles as:

Research

10 pages, 586 KiB  
Article
A Ten-Year Real-Life Experience with Pazopanib in Uterine Leyomiosarcoma in Two High-Specialized Centers in Italy: Effectiveness and Safety
by Mara Mantiero, Marta Bini, Maggie Polignano, Luca Porcu, Roberta Sanfilippo, Chiara Fabbroni, Gabriella Parma, Mariateresa Lapresa, Carmelo Calidona, Cecilia Silvestri, Andrea Franza, Francesco Raspagliesi, Nicoletta Colombo and Monika Ducceschi
Cancers 2024, 16(1), 192; https://doi.org/10.3390/cancers16010192 - 30 Dec 2023
Viewed by 830
Abstract
Background: Uterine leiomyosarcoma (uLMS) is characterized by aggressive behavior associated with a high risk of relapse and mortality. Several therapeutic agents have been employed in the treatment of metastatic disease, with a poor objective response rate. Pazopanib, approved in 2012, is a multi-targeted, [...] Read more.
Background: Uterine leiomyosarcoma (uLMS) is characterized by aggressive behavior associated with a high risk of relapse and mortality. Several therapeutic agents have been employed in the treatment of metastatic disease, with a poor objective response rate. Pazopanib, approved in 2012, is a multi-targeted, orally active small molecule that exerts its effects by inhibiting several tyrosine kinases. To date, poor research on real-life data has been conducted. We aimed to assess the effectiveness and safety of the drug in everyday clinical practice. Methods: We present results of multicenter retrospective data on 38 patients with heavily pretreated metastatic uLMS who underwent oral pazopanib during their therapeutic journey. Results: At a median follow-up of 8.6 months, the disease control rate was 55.2%, with 17% partial responses and 15 patients (39.5%) with stable disease. At a median follow-up of 8.6 months, median progression-free survival was 4 months, and median overall survival was 19.8 months. The most common grade 3 adverse events (AEs) drug-related were hepatic toxicities, diarrhea, hypertension, nausea, and vomiting (all of them with an incidence of 5% considering the whole study cohort). No grade 4 AEs occurred. Conclusions: Pazopanib in everyday clinical practice is safe and shows a good disease control rate with prolonged survival. Full article
(This article belongs to the Special Issue Advances in the Diagnosis and Management of Uterine Sarcomas)
►▼ Show Figures

Figure 1

11 pages, 987 KiB  
Article
Influence of Clinical and Surgical Factors on Uterine Carcinosarcoma Survival
by Myriam Gracia, Yusuf Yildirim, Ronalds Macuks, Rosanna Mancari, Patriciu Achimas-Cadariu, Stephan Polterauer, Sara Iacoponi and Ignacio Zapardiel
Cancers 2023, 15(5), 1463; https://doi.org/10.3390/cancers15051463 - 25 Feb 2023
Cited by 2 | Viewed by 1114
Abstract
Background: The aim of this study was to assess the impact of prognostic factors on the survival of patients diagnosed with uterine carcinosarcoma. Methods: A sub-analysis of the SARCUT study, a multicentric retrospective European study, was carried out. We selected 283 cases of [...] Read more.
Background: The aim of this study was to assess the impact of prognostic factors on the survival of patients diagnosed with uterine carcinosarcoma. Methods: A sub-analysis of the SARCUT study, a multicentric retrospective European study, was carried out. We selected 283 cases of diagnosed uterine carcinosarcoma for the present study. Prognosis factors influencing survival were analyzed. Results: Significant prognostic factors for overall survival were: incomplete cytoreduction (HR = 4.02; 95%CI = 2.68–6.18), FIGO stages III and IV (HR = 3.21; 95%CI = 1.83–5.61), tumor persistence after any treatment (HR = 2.90; 95%CI = 1.97–4.27), presence of extrauterine disease (HR = 2.62; 95%CI = 1.75–3.92), a positive resection margin (HR = 1.56; 95%CI = 1.05–2.34), age (HR = 1.02; 95%CI = 1.00–1.05), and tumor size (HR = 1.01; 95%CI = 1.00–1.01). Significant prognostic factors for disease-free survival were: incomplete cytoreduction (HR = 3.00; 95%CI = 1.67–5.37), tumor persistence after any treatment (HR = 2.64; 95%CI = 1.81–3.86), FIGO stages III and IV (HR = 2.33; 95%CI = 1.59–3.41), presence of extrauterine disease (HR = 2.13; 95%CI = 1.44–3.17), administration of adjuvant chemotherapy (HR = 1.84; 95%CI = 1.27–2.67), a positive resection margin (HR = 1.65; 95%CI = 1.11–2.44), presence of LVSI (HR = 1.61; 95%CI = 1.02–2.55), and tumor size (HR = 1.00; 95%CI = 1.00–1.01). Conclusions: Incomplete cytoreduction, presence of tumor residual after treatment, advanced FIGO stage, extrauterine disease, and tumor size are significant prognostic factors decreasing disease-free survival and overall survival of patients with uterine carcinosarcoma. Full article
(This article belongs to the Special Issue Advances in the Diagnosis and Management of Uterine Sarcomas)
►▼ Show Figures

Figure 1

Show export options expand_more Show export options expand_less
Select all
Export citation of selected articles as:
 
Displaying articles 1-2
Back to TopTop